• NIH Research Involving Introduction of Human Pluripotent Cells into Non-Human Vertebrate Animal Pre-Gastrulation Embryos (NOT-OD-15-158) National Institutes of Health
• Precision Medicine Initiative Cohort Program Recommendations Issued and Accepted (NOT-OD-15-159) National Institutes of Health
• Notice of Participation of the Office of Research Infrastructure Programs in PA-14-154 "Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R43/R44)" (NOT-OD-15-161) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
• Notice Announcing FAQs Page for PAR-14-315 "Testing Interventions for Health-Enhancing Physical Activity (R01) and PAR-14-321 Developing Interventions for Health-Enhancing Physical Activity (R21/R33) (NOT-OD-15-162) Office of Disease Prevention
• Notice of Participation of the National Institute on Aging in PAR-15-346 Time-Sensitive Obesity Policy and Program Evaluation (R01) (NOT-AG-15-017) National Institute on Aging
• Notice to Discontinue NCI Supplements to the Continuing Umbrella of Research Experiences (CURE): P30s, T32s, K12s and R25s (NOT-CA-15-034) National Cancer Institute
• Notice Announcing Pre-Application Webinar for RFA-OD-15-004 "Tobacco Regulatory Science Small Grant Program for New Investigators (R03)" (NOT-OD-16-003) National Institutes of Health
• Request for Information (RFI): Future Directions in Gynecologic Health and Disease Research (NOT-HD-15-030) Eunice Kennedy Shriver National Institute of Child Health and Human Development
• Notice of Plans for NHGRI Implementation of NIH Genomic Data Sharing Policy (NOT-HG-15-038) National Human Genome Research Institute
• Request for Information (RFI): Undiagnosed Diseases Research (NOT-RM-16-001) NIH Roadmap Initiatives
• Request for Information (RFI): Input on Validation Assays for Affinity Reagents Generated by the NIH Common Fund Protein Capture Reagents Program (NOT-RM-16-002) NIH Roadmap Initiatives
• Request for Information (RFI): Soliciting Input for the National Center for Advancing Translational Sciences (NCATS) Strategic Planning Process (NOT-TR-16-002) National Center for Advancing Translational Sciences
• Notice of Intent to Publish a Funding Opportunity Announcement for NCI Supplements to the Continuing Umbrella of Research Experiences (Administrative Supplements to T32 and K12) (NOT-CA-15-036) National Cancer Institute
• Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Molecular and Cellular Analysis Technologies for Cancer Research (R21) (NOT-CA-15-037) National Cancer Institute
• Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (R33) (NOT-CA-15-038) National Cancer Institute
• Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) (NOT-CA-15-039) National Cancer Institute
Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Technologies for Cancer-Relevant Biospecimen Science (R33)  
(NOT-CA-15-040)  
National Cancer Institute

Notice of Correction PAR-13-386 "Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30)" to Delete a Requirement to Group Shared Resources  
(NOT-CA-15-043)  
National Cancer Institute

Advance Notice: NIH Plans to Implement the Federal Awardee Performance and Integrity Information System (FAPIIS) Requirements Beginning January 1, 2016  
(NOT-OD-16-019)  
National Institutes of Health

Notice of National Cancer Institute (NCI) Participation on RFA-AG-16-020 "Impact of Aging on Currently Employed Animal Models of Disease and Chronic Conditions: Demonstration Projects (UH2/UH3)"  
(NOT-CA-15-041)  
National Cancer Institute

Request for Information (RFI): Inviting Comments and Suggestions on the Priorities specified for the NIH-wide Rehabilitation Research Plan  
(NOT-HD-15-032)  
Eunice Kennedy Shriver National Institute of Child Health and Human Development  
National Center for Advancing Translational Sciences  
National Center for Complementary and Integrative Health  
National Cancer Institute  
National Eye Institute  
National Heart, Lung, and Blood Institute  
National Institute on Aging  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
National Institute of Biomedical Imaging and Bioengineering  
Eunice Kennedy Shriver National Institute of Child Health and Human Development  
National Institute on Deafness and Other Communication Disorders  
National Institute of Diabetes and Digestive and Kidney Diseases  
National Institute of Mental Health  
National Institute of Neurological Disorders and Stroke  
National Institute of Nursing Research  
Office of Behavioral and Social Science Research  
Office of Disease Prevention  
Office of Dietary Supplements  
Office of Research on Women's Health

Save the Date for the 2016 NIH Regional Seminar in Baltimore, Maryland - May 11-13  
(NOT-OD-16-026)  
National Institutes of Health

Revised SF424 (R&R) Application Guides and Supplemental Instructions Available for Application Due Dates On and Between January 25, 2016 and May 24, 2016  
(NOT-OD-16-029)  
National Institutes of Health  
Agency for Healthcare Research and Quality

Publication of the Revised NIH Grants Policy Statement (Rev. 11/2015) for FY 2016  
(NOT-OD-16-030)  
National Institutes of Health

Notice of Technical Assistance Webinar for RFA-HL-16-012 "Household Air Pollution (HAP) Health Outcomes Trial (UM1)"  
(NOT-HL-15-285)  
National Heart, Lung, and Blood Institute

Funding opportunities issued for the NIH Precision Medicine Initiative Cohort Program  
(NOT-PM-16-001)  
National Institutes of Health

Notice of Change to Funding Opportunity PAR-15-023 "National Cancer Institute Program Project Applications (P01)"  
(NOT-CA-16-003)  
National Cancer Institute

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01)  
(NOT-DA-16-005)  
National Institute on Drug Abuse  
National Cancer Institute  
National Institute on Alcohol Abuse and Alcoholism  
National Institute on Drug Abuse
• **TITLE:** Household Air Pollution (HAP) Health Outcomes Trial (UM1)  
  **SPONSOR:** National Heart, Lung, and Blood Institute, John E. Fogarty International Center, National Cancer Institute Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, The Common Fund/Office of Strategic Coordination  
  **Synopsis:** This funding opportunity announcement (FOA) seeks applications from institutions/organizations for a cooperative agreement research grant (UM1) to conduct a clinical trial across three or more Low and Middle Income Country (LMIC) settings to test improved stove and fuel interventions on health outcomes in exposed populations. In addition, each application must include a biomarker center element for the development and validation of clinical, physiological, chemical, biochemical and/or microbiological markers of: a) exposure, and b) pathophysiological responses.  
  Application Receipt Date(s): January 19, 2016

• **TITLE:** Limited Competition: Knockout Mouse Phenotyping Project Database (UM1)  
  **SPONSOR:** NIH Roadmap Initiatives, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Research on Women's Health  
  **Synopsis:** This Notice announces modifications to align with standard biographical sketch format that became effective May 25, 2015 (see NOT-OD-15-032). The new standard biographical sketch format will be adopted and the one page attachment for describing the Program Director/Principal Investigator's (PD/PI’s) single most significant publication or research accomplishment will no longer be used. Additionally, the requirement for the applicant to include a statement indicating his/her commitment to devote a minimum of 25% research effort to the New Innovator Award has been moved to the Research Strategy section.  
  Application Receipt Date(s): December 09, 2015

• **TITLE:** Limited Competition: Knockout Mouse Production and Phenotyping Project (UM1)  
  **SPONSOR:** NIH Roadmap Initiatives, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Research on Women's Health  
  **Synopsis:** The purpose of this FOA is to solicit applications for research projects to make maximum progress toward the goal of producing a null-mutant mouse phenotype resource for each gene in mouse strain C57BL/6, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The specific objectives of this FOA are to generate mutant mouse lines using CRISPR/Cas9 technology, perform phenotyping assays, conduct quality control assessments, cryopreserve germplasm, and make mice and data readily available to the research community. The mouse is the ideal mammalian system in which to produce a functional genomics resource because of the long history and depth of understanding of mouse genetics, the sophistication of assistive reproductive technology in the mouse system, short generation times, and the low cost of working with mice in comparison to other mammals. The recent breakthroughs in CRISPR/Cas9 technology make the mouse an even more cost effective model system and will drive technology of mouse production. The goal of this FOA is to support high-throughput broad based phenotyping of approximately 600 null-mutant mouse lines per year, with an overall goal of 3,000 lines for this five-year project period of the Knockout Mouse Phenotyping Program (KOMP2).  
  Application Receipt Date(s): Multiple dates, see announcement.

• **TITLE:** Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UG3/UH3)  
  **SPONSOR:** National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering  
  **Synopsis:** This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs. UG3 applicants should have a working assay or device prototype (not necessarily already capable of cancer applications).
The initial UG3 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use of the device or assay in LMIC settings by meeting specific performance milestones. UG3 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both the UG3 and UH3 phases.

**Application Receipt Date(s): February 09, 2016**

### TITLE: Collaborative Aging (in Place) Research Using Technology (CART) (U2C)
(RFA-AG-16-021)

**SPONSOR:** National Institute on Aging, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, Office of Behavioral and Social Science Research.

**Synopsis:** The purpose of this, Inter-Agency Funding Opportunity Announcement (FOA) is to develop and validate the infrastructure for rapid and effective conduct of future research utilizing technology to facilitate aging in place, with a special emphasis on people from underrepresented groups. This FOA is designed to support Collaborative Aging (in Place) Research Using Technology (CART) by developing and validating a research infrastructure that has the capacity to integrate data across different projects, incorporates existing technologies, and can accommodate future technologies, designed to assess and intervene across a variety of observational and clinical research studies and settings, and for a range of measures, diseases and populations. The infrastructure development will include a demonstration project, to test feasibility for operating on a larger scale. The infrastructure and demonstration project accomplished by this FOA (Phase I) will serve as the foundation for the subsequent large-scale development project for technology research to help reduce hospitalizations, emergency room visits, and admissions to a nursing home for the older population (Phase II). Phase I is designed to be both disease and technology agnostic. Successful multidisciplinary applicants with strong partnerships in engineering, computer science, health and medical research (both public and private sector) are encouraged to apply. Application Receipt Date(s): January 12, 2016

### TITLE: Genomic Data Analysis Network: Processing Genomic Data Center (U24)
(RFA-CA-15-018)

**SPONSOR:** National Cancer Institute

**Synopsis:** This funding opportunity announcement (FOA) is a part of cancer genomics program supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). This FOA solicits applications for a Processing Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-019 and RFA-CA-15-020). The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDAC to be supported under this FOA will be expected to focus on the integration and analysis of data generated by the GCCs and other project participants, development of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.

Application Receipt Date(s): January 27, 2016

### TITLE: Genomic Data Analysis Network: Visualization Genomic Data Center (U24)
(RFA-CA-15-019)

**SPONSOR:** National Cancer Institute

**Synopsis:** This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). This FOA solicits applications for a Visualization Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-018 and RFA-CA-15-020). The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDAC to be supported under this FOA will be expected to focus on the development of visualization tools to facilitate the integration and analysis of data generated by the GCCs and other project participants, development of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process. Application Receipt Date(s): January 27, 2016

### TITLE: Genomic Data Analysis Network: Specialized Genomic Data Center (U24)
(RFA-CA-15-020)

**SPONSOR:** National Cancer Institute

**Synopsis:** This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the
National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). This FOA solicits applications for a Specialized Genomic Data Center that will be a part of the Genomic Data Analysis Network. The network will also include other types of Genome Data Analysis Centers (GDACs) to be supported under companion FOAs, RFA-CA-15-018 and RFA-CA-15-019. The collective goal for all types of GDACs is to enable the cancer research community to develop tools and strategies to analyze the data generated from large-scale genomics projects and support the scientific community at-large in their investigation of the results. The GDACs to be supported under this FOA will be expected to focus on the intensive analysis of discrete sets of genomic platforms (core competencies) to facilitate the integration and analysis of data generated by the GCCs and other project participants, deployment of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses including, but not limited to: systems biology approaches to discovery, pathway analysis models, integrative data analysis methods with accompanying visualization tools to identify complex genomic changes, and integrated cancer biology and translational discovery models that will increase our understanding of cancer as a disease process.

Application Receipt Date(s): January 27, 2016

- **TITLE:** Pre-clinical Research Based on Existing Repurposing Tools (R21)
  **SPONSOR:** National Center for Advancing Translational Sciences
  Application Receipt Date(s): January 13, 2016

- **TITLE:** Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. This FOA solicits applications for multidisciplinary Proteome Characterization Centers (PCCs). PCC awardees will be expected to work as an interactive group and use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens, cultured cells, and animal cancer models) will be provided by the NCI. PCCs will interact with additional CPTAC sub-programs that include: Proteogenomic Data Analysis Centers (PGDAC, to be supported by RFA-CA-15-023) that will conduct integrative analyses of data across the entire proteomes and genomes of cancer types of focus to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-15-022) that will apply state-of-the-art proteomic and proteo-genomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a specific patient’s tumor.
  Application Receipt Date(s): January 27, 2016

- **TITLE:** Proteogenomic Translational Research for Clinical Proteomic Tumor Analysis Consortium (U01)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This FOA solicits applications for multidisciplinary Proteogenomic Translational Research Centers (PTRCs). PTRCs are intended to function as an interactive group focused on applying standardized state-of-the-art proteomic and genomic approaches to clinically relevant research projects. The projects should focus on the proteogenomic aspects in understanding drug responses and resistance to therapies in a clinical context. The proposed projects are expected to be conducted in collaboration with clinical researchers and use human biospecimens from clinical trials. The projects should also involve the use of relevant preclinical models of cancer. Proposed projects are expected to integrate comprehensive proteomics data with genomics data. It is envisioned that these projects will facilitate a rational approach to target cancer related pathways and improve outcomes for patients with cancer. PTRCs will interact with additional CPTAC sub-programs that include: Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-15-023) that will conduct integrative analyses of data across the entire proteomes and genomes of cancer types of focus to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and Proteome Characterization Centers (PCCs, to be supported by RFA-CA-15-021) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens, cultured cells, and animal cancer models) will be provided by the NCI.
  Application Receipt Date(s): January 27, 2016

- **TITLE:** Proteogenomic Data Analysis Centers for Clinical Proteomic Tumor Analysis Consortium (U24)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This FOA solicits applications for multidisciplinary Proteogenomic Data Analysis Centers (PGDACs), which will provide data analysis and biological and clinical interpretation of CPTAC data. PGDAC awardees will be expected to develop computational tools for data analysis, data integration, and visualization and apply these
tools to CPTAC data. PGDACs will interact with additional CPTAC sub-programs that include: Proteome Characterization Centers (PCCs, to be supported by RFA-CA-15-021) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens, cultured cells, and animal cancer models) will be provided by the NCI; and Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-15-022) that will apply state-of-the-art proteomic and proteo-genomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a specific patient’s tumor.

Application Receipt Date(s): January 27, 2016

- **TITLE:** Breast Cancer and the Environment Communication Research Initiative (R03) (RFA-ES-15-015)
  **SPONSORS:** National Institute of Environmental Health Sciences, National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) solicits research projects focused on the process of effective communication of research findings about breast cancer and the environment. A central objective of this new initiative is to ensure effective translation of findings that result in risk messaging that is understood by targeted audiences. The ultimate goal is to provide the scientific evidence for developing communication-based prevention efforts to reduce the risk for breast cancer from environmental factors.
  Application Receipt Date(s): February 10, 2016

- **TITLE:** Breast Cancer and the Environment Communication Research Initiative (R21) (RFA-ES-15-017)
  **SPONSORS:** National Institute of Environmental Health Sciences, National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement encourages research projects focused on the process of effective communication of research findings about breast cancer and the environment. A central objective of this new initiative is to ensure that risk messaging is designed for dissemination and effectively implemented, and leads to individual behavior change or policy change. The ultimate goal is to provide the development, dissemination, and implementation communication-based prevention efforts to reduce the risk for breast cancer from environmental factors.
  Application Receipt Date(s): February 10, 2016

**PROGRAM ANNOUNCEMENTS**

- **TITLE:** Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)
  **SPONSOR:** National Institutes of Health, John E. Fogarty International Center, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Library of Medicine, Office of Dietary Supplements, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, Office of Research on Women's Health, The Common Fund/Office of Strategic Coordination
  **Synopsis:** The Office of Research on Women's Health (ORWH) and participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) announce the continuation of the program for administrative supplements to research grants to support individuals with high potential to re-enter an active research career after an interruption for family responsibilities or other qualifying circumstances. The purpose of these supplements is to encourage such individuals to re-enter research careers within the missions of all the program areas of NIH. This program will provide administrative supplements to existing NIH research grants for the purpose of supporting full-time or part-time research by these individuals to update their existing research skills and knowledge.
  Application Receipt/Submission Date(s): Due dates may vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details.

- **TITLE:** Research Supplements to Promote Diversity in Health Related Research (Admin Supp)
  **SPONSOR:** National Institutes of Health, John E. Fogarty International Center, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and
Bioengineering, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Library of Medicine, Office of Dietary Supplements, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs, The Common Fund/Office of Strategic Coordination

**Synopsis:** The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. Application Receipt/Submission Date(s): Due dates may vary by awarding IC.

**TITLE:** End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01)  
**(PA-15-324)**  
**SPONSOR:** National Institute of Nursing Research, National Cancer Institute, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, Office of Research on Women's Health  
**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers. Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21)  
**(PA-15-325)**  
**SPONSOR:** National Institute of Nursing Research, National Cancer Institute, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, Office of Research on Women's Health  
**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers. Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** Time-Sensitive Obesity Policy and Program Evaluation (R01)  
**(PAR-12-257)**  
**SPONSOR:** National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Aging, National Cancer Institute, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, Office of Behavioral and Social Sciences Research  
**Synopsis:** This announcement establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications to this FOA must demonstrate that the evaluation of an obesity related policy and/or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are eligible for only one submission. It is intended that eligible applications selected for funding will be awarded within 3-4 months after the application submission/receipt date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)  
**(PAR-15-340)**  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
• **TITLE: NCI Outstanding Investigator Award (R35)**
  (PAR-15-342)
  SPONSOR: National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for 7-year grants. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.
  Application Receipt/Submission Date(s): November 23, 2015.

• **TITLE: NCI Mentored Research Scientist Development Award to Promote Diversity (K01)**
  (PAR-15-064)
  SPONSOR: National Cancer Institute
  **Synopsis:** The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor, or sponsor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be underrepresented in health-related science.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)**
  (PAR-15-062)
  SPONSOR: National Cancer Institute
  **Synopsis:** The objective of the NCI Mentored Patient-Oriented Research Career Development Award (K23) program is to provide salary and research support for a sustained period of protected time to ensure a future cadre of well-trained scientists conducting NIH-supported POR. The goal of the NCI DTB K23 is to enhance the diversity of NCI-funded pool of clinical investigators who are available to conduct cancer focused patient-oriented studies, capitalizing on the discoveries of biomedical research and translating them to clinical settings.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08)**
  (PAR-15-060)
  SPONSOR: National Cancer Institute
  **Synopsis:** The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from diverse backgrounds that have been shown to be underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: Advancing Interventions to Improve Medication Adherence (R01)**
  (PA-14-334)
  SPONSOR: National Cancer Institute
  **Synopsis:** FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.
• **TITLE: Advancing Interventions to Improve Medication Adherence (R21)**  
  *(PA-14-335)*  
  **SPONSOR:** Office of Behavioral and Social Sciences Research, National Eye Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Deafness and Other Communication Disorders, National Institute of Mental Health, National Institute of Nursing Research, National Cancer Institute  
  **Synopsis:** This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: Advancing the Science of Geriatric Palliative Care (R03)**  
  *(PA-13-356)*  
  **SPONSOR:** National Institute of Aging, National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This R03 announcement specifically encourages projects primarily aimed at collection of pilot data, demonstration of feasibility, development of new methodology, or other goals of limited scope requiring short-term support. Types of studies may include observational, quasi-experimental, or pilot interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: Advancing the Science of Geriatric Palliative Care (R21)**  
  *(PA-13-355)*  
  **SPONSOR:** National Institute of Aging, National Institute of Nursing Research, National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients’ disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: Advancing the Science of Geriatric Palliative Care (R01)**  
  *(PA-13-354)*  
  **SPONSOR:** National Institute of Aging, National Institute of Nursing Research, National Center for Complementary and Integrative Health, National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients’ disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE: Collaborative Activities to Promote Metabolomics Research (Admin Supp)**  
  *(PAR-13-374)*  
  **SPONSOR:** United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute
**Synopsis:** This Administrative Supplement funding opportunity is part of the Common Fund Metabolomics Program created to increase and improve the nation’s ability to undertake metabolomics analyses in translational and clinical research. This FOA supports supplemental funds to current NIH-funded research projects for new interactive collaborations between basic or clinical researchers and metabolomics experts to add a metabolomics approach to the existing Research Strategy for the project. In addition to enhancing the parent grant by adding metabolomics analyses, collaborative projects must include activities to increase the expertise of the biomedical research group in key aspects of metabolomics study design, analysis, and data interpretation. All applicants are strongly encouraged to discuss potential requests with the awarding IC and with the Common Fund Metabolomics Scientific/Research contact listed below.

- **TITLE:** Examination of Survivorship Care Planning Efficacy and Impact (R21)
  
  **SPONSOR:** National Cancer Institute

  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors’ health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors’ morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

  Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Examination of Survivorship Care Planning Efficacy and Impact (R01)
  
  **SPONSOR:** National Cancer Institute

  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors’ health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors’ morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

  Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)
  
  **SPONSORS:** National Cancer Institute

  **Synopsis:** The purpose of the Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07) is to support the career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences.

  Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** NCI Research Specialist Award (R50)
  
  **SPONSORS:** National Cancer Institute

  **Synopsis:** This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of cancer research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to pursue research within the context of an existing cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, core facility managers, and data scientists, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide desirable salaries and sufficient autonomy so that individuals are not solely dependent on grants held by Principal Investigators for career continuity.

  Application Receipt/Submission Date(s): Multiple dates, see announcement.
TITLE: Revision Applications for Validation of Mobile/Wireless Health Tools for Measurement and Intervention (R01) (PA-16-043)
SPONSORS: Office of Behavioral and Social Science Research, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute on Deafness and Other Communication Disorders, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health
SYNOPSIS: This Funding Opportunity Announcement (FOA) invites revision applications from investigators and institutions/organizations with active NIH-supported research project awards to support an expansion of the scope of approved and funded projects to incorporate recent advances in mobile/wireless tools to validate these tools for measurement and intervention delivery. Revision applications for projects that do not currently employ mobile/wireless tools are welcome provided that the applicant team has the requisite scientific and technical expertise to employ and validate these tools. The focus of this FOA is on recently developed mobile/wireless health tools including sensor technologies and smartphone applications. While some additional programming may be required to customize or integrate the technology into the existing project, this FOA is not intended to support new technology development, but instead to clinically validate recently developed but not yet validated tools.
Application Receipt/Submission Date(s): Multiple dates, see announcement.

TITLE: Image-guided Drug Delivery (R01) (PAR-16-044)
SPONSORS: National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering
SYNOPSIS: This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

OTHER FUNDING OPPORTUNITIES (Sponsors in bold are NIH Peer Reviewed Organizations)

TITLE: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families
SPONSOR: American Cancer Society

TITLE: Clinic and Laboratory Integration Program (CLIP) Grants
SPONSOR: Cancer Research Institute

TITLE: AHNS Pilot Grant
http://www.entnet.org/content/centralized-otolaryngology-research-efforts-core-grants-program

Title: HVTN Research and Mentorship Program (RAMP) Scholar Program for African-American and Latino/a Medical Students
Sponsor: Fred Hutchinson Cancer Research Center, HIV Vaccine Trials Network

TITLE: Biomedical Research Grant (RG)
http://www.lung.org/our-initiatives/research/awards-and-grant-funding/opportunities.html
Sponsors: American Lung Association

TITLE: Travel Grants - AACR Minority-Serving Institution Faculty Scholar in Cancer Research Awards
http://www.aacr.org/Meetings/Pages/Travel_Grants/minority-serving-institution-faculty-scholar-awards__36A82A.aspx
SPONSORS: American Association for Cancer Research

SPONSORS: Avon Foundation for Women